United States & Sun Pharma
24 shared events · Importance 5 · Last updated Aug 20, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Business
United States: US formulations sales declined 9.7% to $427 million due to weakness in generics, including loss of exclusivity for lenalidomide, partially offset by growth in innovative medicines.
Sun Pharma: Sun Pharma reported a 27% rise in Q1 net profit and 10.5% revenue growth, driven by India and innovative medicines, while US generics declined. The company is progressing on its Organon acquisition, expected to close in early 2027.
Jul 31, 2026 · 7 articles
Regulatory
United States: The U.S. is the jurisdiction where the trial occurs, and the case illustrates how domestic legal proceedings can be influenced by international conflicts.
Sun Pharma: Teva is the defendant seeking to exclude references to its Israeli origin to ensure a fair trial. The outcome could affect its legal exposure and reputation.
Aug 06, 2026 · 6 articles
Regulatory
United States: The United States>>> is the market where the United States — Food and Drug Administration>>> accepted the BLA for AVT16, potentially expanding biosimilar options for patients and healthcare providers.
Sun Pharma: Sun Pharma>>> is responsible for the commercialization of AVT16 under a partnership with Alvogen>>>, which could expand its product portfolio if approved.
Jun 08, 2026 · 11 articles
Business
United States: The United States>>> is the target market for the biosimilar applications, with the United States — Food and Drug Administration>>> (FDA) being the regulatory authority for approval.
Sun Pharma: Sun Pharma>>> is partnered with Alvogen>>> for the commercialization of AVT05 and AVT06. The resubmission of BLAs by Alvogen>>> is a positive development for Sun Pharma>>> as it moves closer to potentially commercializing these biosimilars.
Jun 04, 2026 · 10 articles
Business
United States: The expiry of the US-Iran ceasefire without a diplomatic breakthrough contributed to higher oil prices and market uncertainty.
Sun Pharma: Gained, being among the winners.
Aug 19, 2026 · 6 articles
International
United States: Launched airstrikes on Iran and expanded military actions, escalating tensions and driving oil prices higher.
Sun Pharma: Gained as a top gainer.
Jul 06, 2026 · 105 articles
Business
United States: The U.S. is a key market where Teva will commercialize the biosimilar upon approval.
Sun Pharma: Teva secures exclusive global rights to commercialize the biosimilar, advancing its Pivot to Growth strategy and expanding its biosimilars pipeline.
Jul 09, 2026 · 14 articles
Business
United States: US expanded airstrikes on Iran, contributing to global uncertainty and oil price rise.
Sun Pharma: Sun Pharma was among the laggards in the Sensex.
Jul 17, 2026 · 20 articles
Business
United States: The U.S. is a key market for Teva; the FDA's Fast Track designation facilitates development.
Sun Pharma: Teva is the developer of TEV-408 and announced the Phase 2b advancement, which supports its pipeline and growth strategy, positively impacting its stock.
Jul 07, 2026 · 7 articles
Regulatory
United States: The US previously approved Wegovy for MASH in August 2025, setting a precedent for the Indian approval.
Sun Pharma: Sun Pharma also offers generic semaglutide; the expanded Wegovy indication could affect its competitive position.
Jul 17, 2026 · 13 articles
Domestic
United States: US markets ended sharply higher on Tuesday, providing a positive cue for global markets including India.
Sun Pharma: Among laggards, possibly due to profit booking.
Aug 03, 2026 · 20 articles
Business
United States: Three U.S. gambling regulators have commenced reviews into Sportradar, indicating potential regulatory scrutiny and impact on the company's operations within the United States.
Sun Pharma: Sun Pharma is mentioned as a company from which Bleichmar Fonti & Auld LLP previously recovered $420 million.
Apr 23, 2026 · 383 articles
Regulatory
United States: Jurisdiction where the FDA and courts are located; regulatory decisions affect patient access and market dynamics.
Sun Pharma: Teva is mentioned only as a past success for BFA, not directly involved in this event.
Jul 27, 2026 · 293 articles
Business
United States: Country where Palsonify is approved and where most patients reside.
Sun Pharma: Mentioned as part of 2026 M&A activity; acquired Organon for $11.75B.
Jul 06, 2026 · 34 articles
Business
United States: The class action lawsuit is filed in a district court within the United States, indicating the legal jurisdiction of the event.
Sun Pharma: Sun Pharma is mentioned as a past success for Bleichmar Fonti & Auld LLP, where the firm recovered $420 million. This is a historical reference and not directly related to the current event.
May 18, 2026 · 300 articles
International
Sun Pharma: Sun Pharma was among the firms that saw declines in the S&P BSE Sensex.
Jan 08, 2026 · 7 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how United States and Sun Pharma interact across events, view sentiment trends, and discover connected entities.
Open Dashboard